ClinicalTrials.gg
TerminatedNCT01668017Updated Aug 23, 2017Results posted

A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

A Phase 1 interventional study of Pimasertib and Pimasertib in Advanced Solid Tumors and Hepatocellular Carcinoma, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-23.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Treatment

Why this study was terminated
The sponsor decided not to conduct the expansion part of trial (part 2)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies in Carcinoma, Hepatocellular with a site in Japan — 17 open to participants now, 32 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Japan.

Enrollment
88th of 103
26 · median 182
Started
2012
with 4 others
Phase 1
29 of 115
5 open now
Registered
36th of 115
by date

Among the 115 studies in Carcinoma, Hepatocellular with a site in Japan, this one is the 88th largest by enrollment of the 103 interventional ones that give a count, is one of 5 that started in 2012, is one of 29 in phase 1, and was the 36th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 115 studies in Carcinoma, Hepatocellular with a site in Japan are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Carcinoma, Hepatocellular with a site in Japan, or all of them as a file.
02

Study summary

This is a two-part trial. "Solid tumor" in this protocol means solid tumor excluding hepatocellular carcinoma (HCC).

Part 1: Dose Escalation Phase in subjects with solid tumor (Cohort A) and HCC (Cohort B). The dose will be increased from 45 mg twice a day (BID) with 3+3 cohort method up to the recommended phase 2 dose (RP2D) of pimasertib established as single agent in the global studies for each arm independently.

Part 2: The Maximum Tolerated Dose (MTD) defined in Part 1 will be confirmed in more subjects in Cohort A (N=18) and Cohort B (N=6) separately.

Following the recommendation by the Safety Monitoring Committee, Cohort B was discontinued due to hepatocellular carcinoma (HCC) and there will be no further enrollment of subjects to this cohort. This decision is based upon review of safety and efficacy information.

03

Conditions studied

  • Advanced Solid Tumors
  • Hepatocellular Carcinoma

Keywords

  • Advanced solid tumors
  • Hepatocellular carcinoma
  • cancer, liver
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort A: A or cytologically confirmed diagnosis of advanced solid tumors which is either after standard therapy for the disease or for which no effective standard therapy is available. Archived tumor tissue available or of tumor tissue needs to be performed.

Cohort B: A histologically or cytologically confirmed diagnosis of advanced hepatocellular carcinoma (HCC) which is either refractory after standard therapy for the disease or for which no effective standard therapy is available. Archived tumor tissue available or biopsy of tumor tissue needs to be performed. Subjects with A.

  • Male or female Japanese, age greater than or equal to (>=) 18 years.
  • Subject has read and understands the form and is willing and able to give informed consent. The subject fully understands requirements of the trial and is willing to comply with all trial visits and assessments.
  • Women of must have a negative blood pregnancy test at the screening visit.
  • Female subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy by using an adequate method of for 2 weeks prior to, during and four weeks after the last dose medicinal product (IMP).
  • of at least 3 months

Exclusion criteria

Exclusion Criteria:

Hematological abnormality Cohort A: Hematological test abnormalities of \< 9.0 g/dL, \< 1.0*10\^9/L and count \< 100*10\^9/L.

Cohort B: Hematological test abnormalities of Hemoglobin \< 9.0 g/dL, Neutrophil count \< 1.0*10\^9/L, Platelet count \< 75*10\^9/L, subjects with hepatic encephalopathy

  • Renal impairment as evidenced by serum creatinine > 1.5* (ULN), and calculated \< 60 mL/min by Cockcroft-Gault formula.
  • Liver function abnormality of Total > 1.5*ULN, or 9AST) or alkaline phosphatase (ALT)> 2.5*ULN. For subjects with HCC or liver involvement AST/ALT > 5*ULN.
  • History of central nervous system (CNS) , unless subject has been previously treated for
  • History of difficulty swallowing, malabsorption or other chronic gastro-intestinal disease or conditions
  • Performance status (ECOG PS) greater than 1.
  • Has received chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any other anticancer therapy (including any agent) or surgical intervention within 28 days or 5 half lives for non-cytotoxics of registration.
  • Baseline interval on screening (QTc) >= 480 ms or (LVEF) \< 40% on screening echocardiogram
  • Cohort B: Subjects with hepatic encephalopathy, remarkable ascites and subjects with history of esophageal varices rupture within 6 months (subjects with symptom improvement after treatment are eligible)
  • Other serious illness or medical conditions.
  • Retinal degenerative disease.
  • Previous treatment with MEK inhibitors.
  • Legal incapacity or limited legal capacity.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Part 1: Pimasertib 30mg in Solid Tumor

    Drug: Pimasertib

  • Experimental
    Part 1: Pimasertib 45 mg in Solid Tumor

    Drug: Pimasertib

  • Experimental
    Part 1: Pimasertib 60 mg in Solid Tumor

    Drug: Pimasertib

  • Experimental
    Part 1: Pimasertib 30 mg in Hepatocellular Carcinoma (HCC)

    Drug: Pimasertib

  • Experimental
    Part 1: Pimasertib 45 mg in HCC

    Drug: Pimasertib

Interventions

  • Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.

  • Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.

  • Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.

  • Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.

  • Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT)

    DLT defined using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0): any of following toxicities possibly/probably related to study drug: Any non-hematological toxicity of Grade 3 or higher (excluding Grade 3 asymptomatic rise in liver function tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], gamma-glutamyl transferase \[GGT\] reversible in 7 days for subjects with solid tumor and without liver involvement, or Grade 4 for subjects with HCC or with liver involvement; Grade 3 or 4 asymptomatic rise in creatinine phosphokinase (CPK) reversible in 7 days, deniable for myocardial infarction and rhabdomyolysis; Grade 3 vomiting/diarrhea encountered without optimal therapy). Any Grade 4 neutropenia \>5 days duration, any Grade 3 or above febrile neutropenia. Grade 4 thrombocytopenia \>1 day or Grade 3 with bleeding. Any treatment delay \>2 weeks due to drug-related adverse effects.

    Time frame: During Treatment Cycle 1 (Day 1 to 21)

Secondary outcomes

  1. Number of Subjects Who Experienced Treatment-Emergent Adverse Events (TEAEs) or Serious TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to 30 days post last dose of study drug; assessed maximum up to 39.4 weeks

  2. Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 1

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  3. Maximum Observed Concentration (Cmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

    The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  4. Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 15

    Data were not reported for "Part 1: Pimasertib 45 mg in HCC" arm as there were no PK samples collected for this arm.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  5. Maximum Observed Concentration (Cmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

    The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  6. Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 1

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  7. Time to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

    The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  8. Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 15

    Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  9. Time to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

    The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  10. Area Under the Concentration Over Time (AUCt) at Cycle 1 Day 1

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  11. Area Under the Concentration Over Time (AUCt) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

    The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  12. Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 1

    Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours).

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  13. Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib of 1 Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

    Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  14. Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 15

    Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  15. Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

    Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  16. Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 1

    The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  17. Apparent Terminal Half-life (t1/2) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

    The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  18. Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 15

    The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  19. Apparent Terminal Half-life (t1/2) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

    The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  20. Apparent Clearance (CL/f) of Pimasertib on Cycle 1 Day 1

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  21. Apparent Clearance (CL/f) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  22. Apparent Clearance at Steady-state (CLss/f) of Pimasertib on Cycle 1 Day 15

    Apparent clearance at steady state was reported. Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  23. Apparent Clearance at Steady-state (CLss/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

    Apparent clearance at steady state was reported. Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  24. Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 1

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  25. Apparent Volume of Distribution at Terminal Phase (Vz/f) Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

  26. Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 15

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  27. Apparent Volume of Distribution at Terminal Phase (Vz/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The summarized data was not available for this arm therefore individual data was presented.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

  28. Accumulation Ratio for AUC Racc(AUC) of Pimasertib

    Racc (AUC) was calculated as, area under the curve from time zero to end of dosing interval on Day 1 divided by area under the curve from time zero to end of dosing interval on Day 15. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15

  29. Accumulation Ratio for AUC Racc(AUC) of Part 1: Pimasertib 30 mg In HCC Arm

    Racc (AUC) was calculated as, area under the curve from time zero to end of dosing interval on Day 1 divided by area under the curve from time zero to end of dosing interval on Day 15.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15

  30. Accumulation Ratio for Cmax Racc(Cmax) of Pimasertib

    Racc (Cmax) was calculated as, maximum observed plasma concentration on Day 1 (Cmax) divided by maximum observed plasma concentration on Day 15 (Cmax). Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15

  31. Accumulation Ratio for Cmax Racc(Cmax) of Part 1: Pimasertib 30 mg In HCC Arm

    Racc (Cmax) was calculated as, maximum observed plasma concentration on Day 1 (Cmax) divided by maximum observed plasma concentration on Day 15 (Cmax).

    Time frame: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15

  32. Percentage of Subjects With Best Overall Response

    Percentage of subjects with best overall response in each category (complete response \[CR\], partial response \[PR\], stable disease \[SD\], progressive disease \[PD\]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) was reported. CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)

  33. Percentage of Subjects With Objective Response

    Percentage of subjects with objective response (CR plus PR) according to RECIST Version 1.1 was reported. CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)

  34. Percentage of Subjects With Disease Control

    Percentage of subjects with disease control (CR plus PR plus greater than 12 weeks SD) according to RECIST Version 1.1 was reported CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions.

    Time frame: Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)

07

Results

Posted Mar 29, 2017
Limitations and caveats
Due to the Sponsor's decision not to pursue the study drug as monotherapy, the Expansion Phase (Part 2) of the study was not conducted.

Participant flow

First/last subject (informed consent): September 2012/April 2015. Last subject completed: April 2015.

Participant flow — Overall Study
MilestonePart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in Hepatocellular Carcinoma (HCC)Part 1: Pimasertib 45 mg in HCC
Started49652
Completed49652
Not completed00000

Outcome measures

PrimaryNumber of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT)

DLT defined using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0): any of following toxicities possibly/probably related to study drug: Any non-hematological toxicity of Grade 3 or higher (excluding Grade 3 asymptomatic rise in liver function tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], gamma-glutamyl transferase \[GGT\] reversible in 7 days for subjects with solid tumor and without liver involvement, or Grade 4 for subjects with HCC or with liver involvement; Grade 3 or 4 asymptomatic rise in creatinine phosphokinase (CPK) reversible in 7 days, deniable for myocardial infarction and rhabdomyolysis; Grade 3 vomiting/diarrhea encountered without optimal therapy). Any Grade 4 neutropenia \>5 days duration, any Grade 3 or above febrile neutropenia. Grade 4 thrombocytopenia \>1 day or Grade 3 with bleeding. Any treatment delay \>2 weeks due to drug-related adverse effects.

Time frame:
During Treatment Cycle 1 (Day 1 to 21)
Reported as:
Number · subjects
Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT)
subjectsPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCCPart 1: Pimasertib 45 mg in HCC
Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT)00211
SecondaryNumber of Subjects Who Experienced Treatment-Emergent Adverse Events (TEAEs) or Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to 30 days post last dose of study drug; assessed maximum up to 39.4 weeks
Reported as:
Number · subjects
Number of Subjects Who Experienced Treatment-Emergent Adverse Events (TEAEs) or Serious TEAEs
subjectsPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCCPart 1: Pimasertib 45 mg in HCC
TEAEs49652
Serious TEAEs22220
SecondaryMaximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 1
Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 1
nanogram per milliliter (ng/mL)Part 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCC
Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 1162.4 ± 113.1222.1 ± 45.2288.3 ± 52.1167.6 ± 26.3
SecondaryMaximum Observed Concentration (Cmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Number · ng/mL
Maximum Observed Concentration (Cmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
ng/mLPart 1: Pimasertib 45 mg in HCC
Subject 1225
Subject 2281
SecondaryMaximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 15

Data were not reported for "Part 1: Pimasertib 45 mg in HCC" arm as there were no PK samples collected for this arm.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 15
ng/mLPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 45 mg in HCC
Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 15199.5 ± 58.9231.6 ± 66.1336.3 ± 30.8—
SecondaryMaximum Observed Concentration (Cmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Number · ng/mL
Maximum Observed Concentration (Cmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
ng/mLPart 1: Pimasertib 30 mg in HCC
Subject 1320
Subject 2419
SecondaryTime to Reach Maximum Concentration (Tmax) on Cycle 1 Day 1
Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Median · hours
Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 1
hoursPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCC
Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 12.450 (0.48 to 4.00)1.480 (0.48 to 7.98)1.710 (0.97 to 2.43)1.000 (0.95 to 2.57)
SecondaryTime to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Number · hours
Time to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
hoursPart 1: Pimasertib 45 mg in HCC
Subject 11.47
Subject 21.92
SecondaryTime to Reach Maximum Concentration (Tmax) on Cycle 1 Day 15

Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Median · hours
Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 15
hoursPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 45 mg in HCC
Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 151.805 (1.00 to 2.48)1.910 (1.00 to 2.48)2.550 (1.50 to 5.88)—
SecondaryTime to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Number · hours
Time to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
hoursPart 1: Pimasertib 30 mg in HCC
Subject 10.98
Subject 20.95
SecondaryArea Under the Concentration Over Time (AUCt) at Cycle 1 Day 1
Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Over Time (AUCt) at Cycle 1 Day 1
h*ng/mLPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCC
Area Under the Concentration Over Time (AUCt) at Cycle 1 Day 1703.0 ± 73.8862.4 ± 42.81626.9 ± 43.6911.4 ± 27.3
SecondaryArea Under the Concentration Over Time (AUCt) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Number · h*ng/mL
Area Under the Concentration Over Time (AUCt) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
h*ng/mLPart 1: Pimasertib 45 mg in HCC
Subject 11754
Subject 21430
SecondaryArea Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 1

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours).

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 1
h*ng/mLPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCC
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 1618.3 ± 86.1857.4 ± 46.01629.3 ± 43.7911.7 ± 27.2
SecondaryArea Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib of 1 Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Number · h*ng/mL
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib of 1 Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
h*ng/mLPart 1: Pimasertib 45 mg in HCC
Subject 11761
Subject 21431
SecondaryArea Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 15

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 15
h*ng/mLPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 45 mg in HCC
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 151189.3 ± 73.61125.0 ± 62.12140.7 ± 37.6—
SecondaryArea Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Number · h*ng/mL
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
h*ng/mLPart 1: Pimasertib 30 mg in HCC
Subject 12250
Subject 21687
SecondaryApparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 1

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Median · hours
Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 1
hoursPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCC
Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 13.480 (3.43 to 4.78)3.545 (2.77 to 5.24)3.935 (2.71 to 5.61)4.560 (3.27 to 11.5)
SecondaryApparent Terminal Half-life (t1/2) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Number · hours
Apparent Terminal Half-life (t1/2) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
hoursPart 1: Pimasertib 45 mg in HCC
Subject 15.68
Subject 25.46
SecondaryApparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 15

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Median · hours
Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 15
hoursPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 45 mg in HCC
Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 154.235 (0.775 to 5.21)4.000 (3.13 to 5.71)5.530 (2.92 to 8.24)—
SecondaryApparent Terminal Half-life (t1/2) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Number · hours
Apparent Terminal Half-life (t1/2) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
hoursPart 1: Pimasertib 30 mg in HCC
Subject 115.4
Subject 25.41
SecondaryApparent Clearance (CL/f) of Pimasertib on Cycle 1 Day 1

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Geometric mean · liter/hour (L/h)
Apparent Clearance (CL/f) of Pimasertib on Cycle 1 Day 1
liter/hour (L/h)Part 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCC
Apparent Clearance (CL/f) of Pimasertib on Cycle 1 Day 141.67 ± 80.548.17 ± 52.832.62 ± 54.632.19 ± 27.3
SecondaryApparent Clearance (CL/f) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Number · L/h
Apparent Clearance (CL/f) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
L/hPart 1: Pimasertib 45 mg in HCC
Subject 118.5
Subject 223.7
SecondaryApparent Clearance at Steady-state (CLss/f) of Pimasertib on Cycle 1 Day 15

Apparent clearance at steady state was reported. Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Geometric mean · L/h
Apparent Clearance at Steady-state (CLss/f) of Pimasertib on Cycle 1 Day 15
L/hPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 45 mg in HCC
Apparent Clearance at Steady-state (CLss/f) of Pimasertib on Cycle 1 Day 1525.24 ± 73.640.00 ± 62.128.02 ± 37.6—
SecondaryApparent Clearance at Steady-state (CLss/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

Apparent clearance at steady state was reported. Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Number · L/h
Apparent Clearance at Steady-state (CLss/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
L/hPart 1: Pimasertib 30 mg in HCC
Subject 113.3
Subject 217.8
SecondaryApparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 1

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Geometric mean · liters
Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 1
litersPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCC
Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 1231.2 ± 71.6238.1 ± 46.7169.8 ± 29.7177.2 ± 15.9
SecondaryApparent Volume of Distribution at Terminal Phase (Vz/f) Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1
Reported as:
Number · liters
Apparent Volume of Distribution at Terminal Phase (Vz/f) Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
litersPart 1: Pimasertib 45 mg in HCC
Subject 1152
Subject 2187
SecondaryApparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 15

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Geometric mean · liters
Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 15
litersPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 45 mg in HCC
Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 15105.0 ± 161.1233.9 ± 46.4209.1 ± 10.6—
SecondaryApparent Volume of Distribution at Terminal Phase (Vz/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The summarized data was not available for this arm therefore individual data was presented.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15
Reported as:
Number · liters
Apparent Volume of Distribution at Terminal Phase (Vz/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
litersPart 1: Pimasertib 30 mg in HCC
Subject 1297
Subject 2139
SecondaryAccumulation Ratio for AUC Racc(AUC) of Pimasertib

Racc (AUC) was calculated as, area under the curve from time zero to end of dosing interval on Day 1 divided by area under the curve from time zero to end of dosing interval on Day 15. Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15
Reported as:
Geometric mean · ratio
Accumulation Ratio for AUC Racc(AUC) of Pimasertib
ratioPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 45 mg in HCC
Accumulation Ratio for AUC Racc(AUC) of Pimasertib1.782 ± 4.21.382 ± 30.21.311 ± 51.5—
SecondaryAccumulation Ratio for AUC Racc(AUC) of Part 1: Pimasertib 30 mg In HCC Arm

Racc (AUC) was calculated as, area under the curve from time zero to end of dosing interval on Day 1 divided by area under the curve from time zero to end of dosing interval on Day 15.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15
Reported as:
Number · ratio
Accumulation Ratio for AUC Racc(AUC) of Part 1: Pimasertib 30 mg In HCC Arm
ratioPart 1: Pimasertib 30 mg in HCC
Subject 12.43
Subject 21.83
SecondaryAccumulation Ratio for Cmax Racc(Cmax) of Pimasertib

Racc (Cmax) was calculated as, maximum observed plasma concentration on Day 1 (Cmax) divided by maximum observed plasma concentration on Day 15 (Cmax). Data were not reported for "Part 1: Pimasertib 45 mg In HCC" arm as there were no PK samples collected for this arm.

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15
Reported as:
Geometric mean · ratio
Accumulation Ratio for Cmax Racc(Cmax) of Pimasertib
ratioPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 45 mg in HCC
Accumulation Ratio for Cmax Racc(Cmax) of Pimasertib1.227 ± 38.30.8281 ± 65.51.215 ± 61.3—
SecondaryAccumulation Ratio for Cmax Racc(Cmax) of Part 1: Pimasertib 30 mg In HCC Arm

Racc (Cmax) was calculated as, maximum observed plasma concentration on Day 1 (Cmax) divided by maximum observed plasma concentration on Day 15 (Cmax).

Time frame:
Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15
Reported as:
Number · ratio
Accumulation Ratio for Cmax Racc(Cmax) of Part 1: Pimasertib 30 mg In HCC Arm
ratioPart 1: Pimasertib 30 mg in HCC
Subject 11.50
Subject 22.31
SecondaryPercentage of Subjects With Best Overall Response

Percentage of subjects with best overall response in each category (complete response \[CR\], partial response \[PR\], stable disease \[SD\], progressive disease \[PD\]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) was reported. CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)
Reported as:
Number · percentage of subjects
Percentage of Subjects With Best Overall Response
percentage of subjectsPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCCPart 1: Pimasertib 45 mg in HCC
CR00000
PR042.9000
SD014.3000
PD66.742.975.075.050.0
Not evaluable33.3025.025.050.0
SecondaryPercentage of Subjects With Objective Response

Percentage of subjects with objective response (CR plus PR) according to RECIST Version 1.1 was reported. CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)
Reported as:
Number · percentage of subjects
Percentage of Subjects With Objective Response
percentage of subjectsPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCCPart 1: Pimasertib 45 mg in HCC
Percentage of Subjects With Objective Response042.9000
SecondaryPercentage of Subjects With Disease Control

Percentage of subjects with disease control (CR plus PR plus greater than 12 weeks SD) according to RECIST Version 1.1 was reported CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions.

Time frame:
Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)
Reported as:
Number · percentage of subjects
Percentage of Subjects With Disease Control
percentage of subjectsPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCCPart 1: Pimasertib 45 mg in HCC
Percentage of Subjects With Disease Control057.1000

Adverse events

Collected over Baseline up to 30 days post last dose of study drug; assessed maximum up to 39.4 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Pimasertib 30 mg in Solid Tumor—2/4 (50%)4/4 (100%)
Part 1: Pimasertib 45 mg in Solid Tumor—2/9 (22.2%)9/9 (100%)
Part 1: Pimasertib 60 mg in Solid Tumor—2/6 (33.3%)6/6 (100%)
Part 1: Pimasertib 30 mg in HCC—2/5 (40%)5/5 (100%)
Part 1: Pimasertib 45 mg in HCC—0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCCPart 1: Pimasertib 45 mg in HCC
PyrexiaGeneral disorders0/40/90/62/50/2
Disease progressionGeneral disorders1/40/90/60/50/2
Liver disorderHepatobiliary disorders1/40/90/60/50/2
General physical health deteriorationGeneral disorders0/40/91/60/50/2
InfectionInfections and infestations0/40/91/60/50/2
Muscular weaknessMusculoskeletal and connective tissue disorders0/40/91/60/50/2
Jaundice cholestaticHepatobiliary disorders0/41/90/60/50/2
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders0/41/90/60/50/2
Most frequent other events
Showing 10 of 96
Most frequent other events
EventPart 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCCPart 1: Pimasertib 45 mg in HCC
VomitingGastrointestinal disorders0/41/93/61/52/2
Blood creatine phosphokinase increasedInvestigations4/46/95/62/50/2
Retinal detachmentEye disorders3/46/95/63/51/2
Vision blurredEye disorders3/46/95/63/51/2
Dermatitis acneiformSkin and subcutaneous tissue disorders1/46/93/64/50/2
Aspartate aminotransferase increasedInvestigations3/45/91/62/51/2
StomatitisGastrointestinal disorders1/41/94/62/50/2
Oedema peripheralGeneral disorders1/45/94/60/51/2
DiarrhoeaGastrointestinal disorders1/45/93/63/51/2
Retinal haemorrhageEye disorders0/42/90/60/51/2

Baseline characteristics

Safety analysis set included all subjects who received at least one administration of pimasertib.

Age, Continuous
Age, Continuous(years)Part 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCCPart 1: Pimasertib 45 mg in HCCTotal
Mean62.3 ± 12.2061.4 ± 10.6361.5 ± 9.2958.8 ± 13.6356.5 ± 20.5160.7 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Pimasertib 30 mg in Solid TumorPart 1: Pimasertib 45 mg in Solid TumorPart 1: Pimasertib 60 mg in Solid TumorPart 1: Pimasertib 30 mg in HCCPart 1: Pimasertib 45 mg in HCCTotal
Female2442113
Male2523113
08

Study locations

1 site
  • Please contact
    Merck Serono Co., Ltd for recruiting locations in, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2012 to primary completion in May 2015, 32 months.

Results were first posted in Mar 2017, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2012
First posted
Aug 17, 2012
StartActual
Sep 30, 2012
Primary completionActual
May 31, 2015
CompletionActual
May 31, 2015
Results first posted
Mar 29, 2017
Last update
Aug 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01668017
Collaborators
Merck Serono Co., Ltd., Japan
Responsible party
Sponsor
First posted
Aug 17, 2012
Start date
Sep 30, 2012
Primary completion
May 31, 2015
Completion
May 31, 2015
Results posted
Mar 29, 2017
Last update
Aug 23, 2017

Study contacts

Medical Responsible
study director · Merck Serono Co., Ltd., Tokyo, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimasertib

Start the discussion